Home›Legal›Tirzepatide in Florida
Tirzepatide in Florida: Legal Status & Provider Guide (2026)
Quick Answer
Tirzepatide is a prescription substance in the United States. Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist. The compounding shortage exemption expired in early 2025. Current federal law generally prohibits compounded tirzepatide outside of narrow exceptions. Providers offering compounded tirzepatide should have clear documentation of their legal basis. In Florida, compounding is governed by the Florida Board of Pharmacy (FBP). In Florida, advanced practice registered nurses (APRNs) with prescriptive authority and physician assistants may prescribe compounded peptides within the scope of their collaborative agreement. Florida's telehealth laws permit prescribing without prior in-person visit in many contexts, which has made Florida a hub for telehealth peptide programs. Prescribers must hold a Florida license to prescribe to Florida patients.
Federal Legal Status
FDA Approval Status
FDA-approved as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023). FDA declared the tirzepatide shortage resolved in December 2024.
Compounding Pharmacy Rules (Federal)
Compounded tirzepatide was broadly permitted during the shortage period. Following FDA's shortage resolution in December 2024, 503B outsourcing facilities had until February 18, 2025, and 503A pharmacies until March 19, 2025, to wind down compounding. As of mid-2025, compounded tirzepatide is generally prohibited except for narrow clinical exceptions under a valid prescription.
Also Known As
Mounjaro · Zepbound
Primary Research Areas
- Weight management
- Type 2 diabetes
- Metabolic health
- Insulin resistance
Florida Pharmacy Board & Compounding Rules
Regulator
Compounding Overview
Florida has a large and active compounding pharmacy sector. The Florida Board of Pharmacy (Department of Health) regulates sterile and non-sterile compounding, requiring separate permits for each type. Florida pharmacies that compound sterile preparations must comply with USP 797 and undergo periodic inspections. Florida has specific rules for "office use" compounding — a provision that allows prescribers to order pre-mixed sterile compounds for use in their offices, which is relevant to many peptide clinics.
Notable Rules
- Florida requires separate permits for sterile and non-sterile compounding.
- Florida allows "office use" compounding with specific restrictions — relevant to many peptide clinical practices.
- USP 797 compliance is mandatory for all sterile compounding facilities.
- Florida telehealth laws are permissive by national standards, making the state a major market for telehealth peptide programs.
- Out-of-state pharmacies must be registered with the Florida Board of Pharmacy to ship into the state.
Prescribing Requirements in Florida
In Florida, advanced practice registered nurses (APRNs) with prescriptive authority and physician assistants may prescribe compounded peptides within the scope of their collaborative agreement. Florida's telehealth laws permit prescribing without prior in-person visit in many contexts, which has made Florida a hub for telehealth peptide programs. Prescribers must hold a Florida license to prescribe to Florida patients.
About Tirzepatide
Tirzepatide is a novel dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist developed by Eli Lilly. It has demonstrated significant efficacy in clinical trials for both glycemic control and weight reduction, with some studies showing superior weight loss compared to semaglutide.
For more research information, mechanism of action, and provider availability, see the Tirzepatide research profile on PeptideBase.
Frequently Asked Questions
- Is compounded tirzepatide legal in 2026?
- FDA declared the tirzepatide shortage resolved in December 2024. Wind-down periods ended in Q1 2025. As of mid-2025, compounded tirzepatide is generally prohibited except for documented clinical exceptions. Patients should verify the legal basis with their provider.
- What is the difference between Mounjaro and Zepbound?
- Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes management; Zepbound is approved for chronic weight management in adults with obesity or overweight with a related condition. The drugs are chemically identical.
Tirzepatide Providers in Florida
No providers currently listed in Florida for Tirzepatide. Browse the full directory to find providers offering Tirzepatide.
Browse all Tirzepatide providers →Tirzepatide Legal Status in Other States
Pharmacy board rules and compounding regulations vary by state. Compare Tirzepatide legal status across other major markets:
Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: .